Investor Relations
|
Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, Utah 84108
U.S.A.
Phone: 801-584-3600
Fax: 801-584-3640
E-Mail: info@myriad.com |
 |
Key Statistics |
|
|
| Industry: |
Biotechnology |
| Segment: |
Biopharmaceuticals |
| Ownership: |
Public |
| Exchange: |
NASDAQ |
| Symbol: |
MYGN |
| SEC: |
SEC Filings |
Myriad Genetics is a leading biopharmaceutical company focused
on the development of novel healthcare products. Myriad has
a full pipeline of preclinical drug candidates in development
including two Phase I human clinical trials for cancer drugs,
Azixa™ and MPC-2130. The Company markets molecular diagnostic
tests to determine the risk of breast cancer, ovarian cancer, colon
cancer, endometrial cancer and melanoma skin cancer in individuals
with a family history of cancer.
|
